BRAINSTORM CELL THERAPEUTICS INC.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
BCLI$1.14-7.3%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| · 2024 · 2023 | ||||||
| | U.S. $ in thousands | |||||
| ASSETS | | | ||||
| | | | | | | |
| Current Assets: · · · · | ||||||
| Cash and cash equivalents | | $187 | | $1,300 | ||
| Other accounts receivable | | 63 | | 51 | ||
| Prepaid expenses and other current assets | | 135 | | 548 | ||
| Total current assets | | $385 | | $1,899 | ||
| | | | | | | |
| Long-Term Assets: | | | | | ||
| Prepaid expenses and other long-term assets | | $22 | | $22 | ||
| Restricted Cash | | | 184 | | | 185 |
| Operating lease right of use asset (Note 4) | | | 807 | | | 1,416 |
| Property and Equipment, Net (Note 5) | | 434 | | 686 | ||
| Total Long-Term Assets | | $1,447 | | $2,309 | ||
| | | | | | | |
| Total assets | | $1,832 | | $4,208 | ||
| | | | | | | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | | | | | ||
| | | | | | | |
| Current Liabilities: | | | | | ||
| Accounts payables | | $6,080 | | $4,954 | ||
| Accrued expenses | | 619 | | 1,240 | ||
| Related party (Note 11) | | | 300 | | | — |
| Operating lease liability (Note 4) | | | 549 | | | 603 |
| Employees related liability | | 1,430 | | 1,003 | ||
| Total current liabilities | | $8,978 | | $7,800 | ||
| | | | | | | |
| Long-Term Liabilities: | | | | | | |
| Operating lease liability (Note 4) | | | 171 | | | 672 |
| Warrants liability (Note 7) | | | 447 | | | 594 |
| Total long-term liabilities | | $618 | | $1,266 | ||
| | | | | | | |
| Total liabilities | | $9,596 | | $9,066 | ||
| | | | | | | |
| Stockholders’ Deficit: | | | | | ||
| Stock capital: (Note 8) | | 14 | | 13 | ||
| Common Stock of $0.00005 par value - Authorized: 250,000,000 shares at December 31, 2024 and 100,000,000 shares at December 31, 2023 respectively; Issued and outstanding: 6,141,762 and 4,032,614 shares at December 31, 2024 and December 31, 2023 respectively (*) | | | | | | |
| Additional paid-in-capital | | 218,974 | | 210,258 | ||
| Treasury stocks | | (116) | | (116) | ||
| Accumulated deficit | | (226,636) | | (215,013) | ||
| Total stockholders’ deficit | | $(7,764) | | $(4,858) | ||
| | | | | | | |
| Total liabilities and stockholders’ deficit | | $1,832 | | $4,208 | ||
*Retroactively adjusted (See Note 8).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.